Browse Articles
Discover research articles across all indexed journals
Entropy difference-based EEG channel selection technique for automated detection of ADHD
Attention deficit hyperactivity disorder (ADHD) is one of the common neurodevelopmental disorders in children. This paper presents an automated approach for ADHD detection using the proposed entropy difference (EnD)-based encephalogram (EEG) channel selection approach. In the proposed approach, we selected the most significant EEG channels for the accurate identification of ADHD using an EnD-based channel selection approach. Secondly, a set of features is extracted from the selected channels and fed to a classifier. To verify the effectiveness of the channels selected, we explored three sets of features and classifiers. More specifically, we explored discrete wavelet transform (DWT), empirical mode decomposition (EMD) and symmetrically-weighted local binary pattern (SLBP)-based features. To perform automated classification, we have used k-nearest neighbor (k-NN), Ensemble classifier, and support vectors machine (SVM) classifiers. Our proposed approach yielded the highest accuracy of 99.29% using the public database. In addition, the proposed EnD-based channel selection has consistently provided better classification accuracies than the entropy-based channel selection approach. Also, the developed method has outperformed the existing approaches in automated ADHD detection.
Glucagon like peptide-1 modulates urinary sodium excretion in diabetic kidney disease via ENaC activation
Development of a multivariable prognostic prediction model for skin tears in older nursing home residents
Abstract Skin tears are traumatic wounds and are among the most prevalent skin conditions in older adults, particularly those in long-term care facilities. These injuries can lead to complications such as infection, pain, reduced quality of life, and increased healthcare costs. This study aimed to identify risk factors for skin tear development in nursing home residents aged 65 years or older and to develop a predictive prognostic model. A secondary data analysis was performed on long-term care nursing home residents ≥ 65 years who participated in a cluster-randomized controlled clinical trial conducted in Berlin, Germany, from April 2019 to June 2021. A total of 101 residents were included. At week 12, 19 residents (18.8%) developed at least one skin tear. The best-fit predictive model identified lower Body Mass Index, lower Barthel Index scores, presence of xerosis cutis on the legs, and regular corticosteroid use as significant risk factors for skin tear development. The model demonstrated good discriminatory ability (area under the curve: 0.823), with sensitivity and specificity rates of 73.7% and 74.4%, respectively. These risk factors could help identify at-risk individuals, enabling targeted preventive measures. However, the model requires validation in a prospective cohort to confirm its applicability in clinical practice.
Creation of knockin mice for the fluorescence protein based in vivo identification of skeletal myofiber types
A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma
Abstract Prizloncabtagene autoleucel (prizlon-cel), a novel bispecific chimeric antigen receptor T cell, targets and eliminates CD19/CD20-positive tumor cells. This phase 1, open-label study investigated the safety and efficacy of prizlon-cel in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). Patients with CD19 and/or CD20-positive R/R B-NHL received a 3-day lymphodepletion (cyclophosphamide: 300 mg/m2 per day; fludarabine: 30 mg/m2 per day) followed by an IV dose of prizlon-cel. The primary end points were dose-limiting toxicity (DLT) and incidence and severity of treatment-emergent adverse events (TEAEs). Secondary end points included overall response rate (ORR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS). Of the 48 patients infused prizlon-cel, 44 had large B-cell lymphoma (LBCL). No patient experienced DLT. Cytokine release syndrome occurred in 93.8% of the patients, with only 1 case of grade 3. Immune effector cell-associated neurotoxicity syndrome occurred in 6.3% of patients, with no grade 3 or higher events. The most common grade 3 or higher TEAEs were neutropenia (83.3%) and leukopenia (50%). The ORR and complete response (CR) rates in all patients were 91.5% and 85.1%, respectively, and in LBCL patients, ORR was 90.7% with 86.0% CR. With median follow-up of 30.0 months, median DOR, PFS, and OS were all not reached. Kaplan-Meier estimate of 2-year DOR, PFS, and OS rates were 66.0%, 62.6%, and 76.5%, respectively. Prizlon-cel had a favorable safety profile and a high and durable response in patients with R/R B-NHL, suggesting a promising treatment option for patients with R/R B-NHL. These trials were registered at www.clinicaltrials.gov as #NCT04317885, #NCT04655677, #NCT04696432, and #NCT04693676.
Dementia classification using two-channel electroencephalography features
A brain drain would impoverish the United States and diminish world science
X-linked sideroblastic anemia in females
Abstract X-linked sideroblastic anemia (XLSA) in female carriers of 5-aminolevulinic acid synthase 2 mutations is not uncommon. We describe unique features and genotype/phenotype correlations in females with XLSA and evaluate the contributions of X-chromosome skewing and clonal hematopoiesis, emphasizing the importance of distinguishing it from myelodysplastic syndromes with ring sideroblasts.
Identifying six single nucleotide variants in the COL17A1 gene that alter RNA splicing: database analysis and minigene assays
Incorporation of immunotherapy into frontline treatment for adults with B-cell precursor acute lymphoblastic leukemia
Abstract Although complete remission rates in adults with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) have improved over the last 2 decades, it is still inferior to that of the pediatric population, and once in remission, the risk of relapse is still high. Furthermore, although pediatric-inspired chemotherapy regimens have improved long-term outcomes for adolescents and young adults, these intensive chemotherapy regimens are not well tolerated in older patients and are associated with higher morbidity and mortality. Immunotherapeutic agents offer a potential opportunity to improve response and decrease relapse without increasing toxicity. The incorporation of rituximab (anti-CD20 monoclonal antibody) into chemotherapy regimens has been shown to improve outcomes. The treatment of BCP-ALL in adults has been transformed with the approval of inotuzumab ozogamicin (anti-CD22 antibody-drug conjugate), blinatumomab (CD3/CD19 bispecific antibody construct), and chimeric antigen receptor T cells for relapsed or refractory disease and of blinatumomab for measurable residual disease (MRD)–positive remission. More recently, studies of inotuzumab and blinatumomab have shown promising results when used up front either with or without multiagent chemotherapy. Blinatumomab has also been shown in a randomized trial to provide a survival benefit in patients with MRD-negative first remission when added to chemotherapy, which recently led to its additional US Food and Drug Administration approval for use in consolidation. In this review, we highlight the evolution of chemoimmunotherapy-based treatment approaches in the management of treatment-naïve BCP-ALL.
Publisher Correction: Probing the local thermal expansion coefficient of single liquid Sn nanoparticles using EELS in STEM
How seahorses and pipefish inspired the design of a boat propeller
Introduction to a review series on acute lymphoblastic leukemia
Our understanding of the biology of acute lymphoblastic leukemia (ALL) continues to be refined, and these advances naturally lead to improvements in therapy and outcomes for pediatric and adult patients. Associate Editor Hervé Dombret introduces this series of reviews that bring readers up to date with the biology of both B-cell and T-cell ALL (B-ALL and T-ALL) as well as the latest approaches to first-line therapy. Passet et al discuss the different genetic subtypes of B-ALL and their implications, while Pölönen and colleagues discuss T-ALL, highlighting how biology informs classification and in turn prognostication and therapy. Badar and coauthors explore how the incorporation of immunotherapy is revolutionizing treatment regimens. Finally, Rampotas and Roddie focus specifically on the role of chimeric antigen receptor T cells in management of patients with B-ALL now and in the future.
Phosphoglucomutase 5 gene transcripts are expressed by the human placenta and differentially regulated in placental dysfunction
Progressive chromatin rewiring by ETO2::GLIS2 revealed in a genome-edited human iPSC model of pediatric leukemia initiation
Abstract Pediatric acute myeloid leukemia frequently harbors fusion oncogenes associated with poor prognosis, including KMT2A, NUP98, and GLIS2 rearrangements. Although murine models have demonstrated their leukemogenic activities, the steps from a normal human cell to leukemic blasts remain unclear. Here, we precisely reproduced the inversion of chromosome 16 resulting in the ETO2::GLIS2 fusion in human induced pluripotent stem cells (iPSCs). iPSC-derived ETO2::GLIS2-expressing hematopoietic cells showed differentiation alterations in vitro and efficiently induced in vivo development of leukemia that closely phenocopied human acute megakaryoblastic leukemia (AMKL), reflected by flow cytometry and single-cell transcriptomes. Comparison of iPS-derived cells with patient-derived cells revealed altered chromatin accessibility at early and later bona fide leukemia stages, with aberrantly higher accessibility and expression of the osteogenic homeobox factor DLX3 that preceded increased accessibility to ETS factors. DLX3 overexpression in normal CD34+ cells increased accessibility to ETS motifs and reduced accessibility to GATA motifs. A DLX3 transcriptional module was globally enriched in both ETO2::GLIS2 AMKL and some aggressive pediatric osteosarcoma. Importantly, DLX3 knockout abrogated leukemia initiation in this ETO2::GLIS2 iPSC model. Collectively, the characterization of a novel human iPSC-derived AMKL model revealed that hijacking of the osteogenic homeobox transcription factor DLX3 is an essential early step in chromatin changes and leukemogenesis driven by the ETO2::GLIS2 fusion oncogene.
Nature-based solutions could offset coastal squeeze of tidal wetlands from sea-level rise on the U.S. Pacific coast
Abstract In this study, we explored the opportunities for tidal wetland landward migration in response to sea-level rise on the Pacific Coast of the United States. By employing a systematic spatial approach, we quantified the available space for wetland migration with sea-level rise across 61 estuarine drainage areas. Although many of the existing tidal wetlands are small patches, our analyses show that 63% of the estuaries lacked the landward migration space needed to replace current tidal wetland extent, thereby threatening a wide range of protected species and ecosystem services. Developed lands and steep topography represent common barriers to migration along the Pacific coast, especially in central and southern California. The available wetland migration space consists primarily of agriculture, pasture, and freshwater wetlands, with most of the area available for migration occurring in just a few watersheds. In most watersheds tidal wetland migration would only occur with human intervention or facilitation. The greatest amount of area available for wetland migration was in the San Francisco Bay-Delta and Columbia River estuaries, together accounting for 58% of all available migration space on the Pacific Coast. Nature-based solutions to reduce tidal wetland loss from sea-level rise can include restoration in suitable areas, removal of barriers to tidal wetland migration, and elevation building approaches. Tidal wetland restoration opportunities could increase area by 59%, underscoring it as a plausible approach to prevent tidal wetland loss in those estuaries and a viable Nature-based solution. 54% of estuaries building elevations of existing tidal wetlands may be the most feasible approach needed. Our analyses illustrate the importance of management efforts that use Nature-based approaches to prevent tidal wetland ecosystem and species loss over the coming decades from sea-level rise.